Literature DB >> 2140341

Immunogenic properties of Pseudomonas aeruginosa mucoid exopolysaccharide.

C V Garner1, D DesJardins, G B Pier.   

Abstract

Previous studies have shown that antibodies to Pseudomonas aeruginosa mucoid exopolysaccharide (MEP) can be divided into two types on the basis of their functional activity. One type is able to mediate opsonic killing in conjunction with leukocytes and complement, and the other type is not. We investigated, in mice, the properties of this antigen associated with elicitation of opsonic killing antibody. We found that smaller-sized material (Kav = 0.26), which has been tested as a human vaccine, elicited opsonic killing antibody in mice at low doses (1 to 10 micrograms) and at doses of greater than or equal to 40 micrograms, only nonopsonic killing antibody was produced. A similar dose effect was seen with heat-killed mucoid P. aeruginosa cells. After immunization with high doses of this MEP or the heat-killed cells, the mice were refractory to induction of opsonic killing antibody no matter what dose of MEP was used as a booster. In contrast, a larger-molecular-weight preparation (Kav = 0.05) elicited opsonic killing antibody over a wide dose range (1 to 400 micrograms). Additionally, 50 micrograms of the larger-sized preparation could overcome the suppression induced by 50 micrograms of the smaller material. Suppression elicited by 50 micrograms of the smaller material could be adoptively transferred to nonimmune mice with the T-cell fraction of spleen cells. These results indicate that both molecular size and dose are critical determinants for eliciting opsonic killing antibody to mucoid P. aeruginosa after immunizing with MEP.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2140341      PMCID: PMC258732          DOI: 10.1128/iai.58.6.1835-1842.1990

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  20 in total

1.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

Authors:  M M Bradford
Journal:  Anal Biochem       Date:  1976-05-07       Impact factor: 3.365

Review 2.  Cystic fibrosis.

Authors:  R E Wood; T F Boat; C F Doershuk
Journal:  Am Rev Respir Dis       Date:  1976-06

Review 3.  The gamma delta T cell receptor.

Authors:  M B Brenner; J L Strominger; M S Krangel
Journal:  Adv Immunol       Date:  1988       Impact factor: 3.543

4.  "Panning" for lymphocytes: a method for cell selection.

Authors:  L J Wysocki; V L Sato
Journal:  Proc Natl Acad Sci U S A       Date:  1978-06       Impact factor: 11.205

5.  A new modification of the carbazole analysis: application to heteropolysaccharides.

Authors:  C A Knutson; A Jeanes
Journal:  Anal Biochem       Date:  1968-09       Impact factor: 3.365

6.  Direct demonstration of specific suppressor T cells in the mice tolerant to type III pneumococcal polysaccharide: two-step requirement for development of detectable suppressor cells.

Authors:  H Braley-Mullen
Journal:  J Immunol       Date:  1980-10       Impact factor: 5.422

7.  Mucoid strains of Pseudomonas aeruginosa: the influence of culture medium on the stability of mucus production.

Authors:  J R Govan
Journal:  J Med Microbiol       Date:  1975-11       Impact factor: 2.472

8.  Safety and immunogenicity of high molecular weight polysaccharide vaccine from immunotype 1 Pseudomonas aeruginosa.

Authors:  G B Pier
Journal:  J Clin Invest       Date:  1982-02       Impact factor: 14.808

9.  Induction in mice of cell-mediated immunity to Pseudomonas aeruginosa by high molecular weight polysaccharide and vinblastine.

Authors:  G B Pier; R B Markham
Journal:  J Immunol       Date:  1982-05       Impact factor: 5.422

10.  Immunochemical characterization of the mucoid exopolysaccharide of Pseudomonas aeruginosa.

Authors:  G B Pier; W J Matthews; D D Eardley
Journal:  J Infect Dis       Date:  1983-03       Impact factor: 5.226

View more
  15 in total

Review 1.  Clinical significance of microbial infection and adaptation in cystic fibrosis.

Authors:  Alan R Hauser; Manu Jain; Maskit Bar-Meir; Susanna A McColley
Journal:  Clin Microbiol Rev       Date:  2011-01       Impact factor: 26.132

2.  Evaluation of flagella and flagellin of Pseudomonas aeruginosa as vaccines.

Authors:  Victoria L Campodónico; Nicolás J Llosa; Martha Grout; Gerd Döring; Tomás Maira-Litrán; Gerald B Pier
Journal:  Infect Immun       Date:  2009-12-07       Impact factor: 3.441

3.  Human monoclonal antibodies against Pseudomonas aeruginosa lipopolysaccharide derived from transgenic mice containing megabase human immunoglobulin loci are opsonic and protective against fatal pseudomonas sepsis.

Authors:  S Hemachandra; K Kamboj; J Copfer; G Pier; L L Green; J R Schreiber
Journal:  Infect Immun       Date:  2001-04       Impact factor: 3.441

4.  Efficacy of a conjugate vaccine containing polymannuronic acid and flagellin against experimental Pseudomonas aeruginosa lung infection in mice.

Authors:  Victoria L Campodónico; Nicolas J Llosa; Leticia V Bentancor; Tomas Maira-Litran; Gerald B Pier
Journal:  Infect Immun       Date:  2011-05-31       Impact factor: 3.441

5.  Immunization with Pseudomonas aeruginosa vaccines and adjuvant can modulate the type of inflammatory response subsequent to infection.

Authors:  H K Johansen; F Espersen; S J Cryz; H P Hougen; A Fomsgaard; J Rygaard; N Høiby
Journal:  Infect Immun       Date:  1994-08       Impact factor: 3.441

Review 6.  Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia.

Authors:  J R Govan; V Deretic
Journal:  Microbiol Rev       Date:  1996-09

7.  Immune complexes from immunized mice and infected cystic fibrosis patients mediate murine and human T cell killing of hybridomas producing protective, opsonic antibody to Pseudomonas aeruginosa.

Authors:  G B Pier; S Takeda; M Grout; R B Markham
Journal:  J Clin Invest       Date:  1993-03       Impact factor: 14.808

8.  Construction and characterization of a Pseudomonas aeruginosa mucoid exopolysaccharide-alginate conjugate vaccine.

Authors:  Christian Theilacker; Fadie T Coleman; Simone Mueschenborn; Nicolas Llosa; Martha Grout; Gerald B Pier
Journal:  Infect Immun       Date:  2003-07       Impact factor: 3.441

9.  Suppression of lymphocyte and neutrophil functions by Pseudomonas aeruginosa mucoid exopolysaccharide (alginate): reversal by physicochemical, alginase, and specific monoclonal antibody treatments.

Authors:  G T Mai; W K Seow; G B Pier; J G McCormack; Y H Thong
Journal:  Infect Immun       Date:  1993-02       Impact factor: 3.441

10.  Prophylactic and therapeutic efficacy of a fully human immunoglobulin G1 monoclonal antibody to Pseudomonas aeruginosa alginate in murine keratitis infection.

Authors:  Tanweer Zaidi; Gerald B Pier
Journal:  Infect Immun       Date:  2008-07-21       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.